Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
D000135:Acid Phosphatase / Q000032:analysis; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000032:analysis; D004962:Estranes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006331:Heart Diseases / Q000150:complications; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011467:Prostate / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D002219:Carbamates; D002272:Carcinoembryonic Antigen; D004962:Estranes; D009588:Nitrogen Mustard Compounds; D009943:Organophosphorus Compounds; D000135:Acid Phosphatase